Full Year
PPCB — FY2026 Annual Report Analysis (Year Ended June 30, 2026)
Propanc Biopharma's net loss narrowed to $18.9M from $58.9M on far less stock-based pay, but operating cash burn rose to $5.7M, year-end cash was $0.83M and the share count reached 6.3M.